Galectin Therapeutics (GALT) Receiving Critical Press Coverage, Report Shows

News articles about Galectin Therapeutics (NASDAQ:GALT) have been trending negative this week, according to AlphaOne Sentiment Analysis. The research firm, a division of Accern, identifies positive and negative media coverage by reviewing more than twenty million news and blog sources. AlphaOne ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Galectin Therapeutics earned a news impact score of -0.33 on AlphaOne’s scale. AlphaOne also assigned news coverage about the company an impact score of 47 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the news articles that may have impacted Alpha One’s analysis:

Insider Buying and Selling by Quarter for Galectin Therapeutics (NASDAQ:GALT)

GALT has been the topic of a number of recent analyst reports. Zacks Investment Research raised shares of Galectin Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a report on Tuesday. FBR & Co reissued a “market perform” rating and issued a $2.00 price target on shares of Galectin Therapeutics in a report on Monday, April 3rd. Finally, HC Wainwright raised shares of Galectin Therapeutics from a “neutral” rating to a “buy” rating and set a $3.50 price target on the stock in a report on Thursday, March 30th.

Shares of Galectin Therapeutics (NASDAQ:GALT) traded down 5.62% during midday trading on Friday, hitting $2.35. 299,689 shares of the stock were exchanged. The stock’s market cap is $81.47 million. The firm’s 50 day moving average price is $2.59 and its 200-day moving average price is $1.87. Galectin Therapeutics has a 52-week low of $0.49 and a 52-week high of $3.68.

Galectin Therapeutics (NASDAQ:GALT) last posted its quarterly earnings results on Monday, May 15th. The company reported ($0.15) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.16) by $0.01. On average, equities research analysts expect that Galectin Therapeutics will post ($0.50) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Galectin Therapeutics (GALT) Receiving Critical Press Coverage, Report Shows” was reported by Markets Daily and is owned by of Markets Daily. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at

About Galectin Therapeutics

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.

Receive News & Ratings for Galectin Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply